CAJ | 학술논문

背景与目的：随着硼替佐米成功用于多发性骨髓瘤的治疗，药物导致带状疱疹激活现象受到关注。本研究探讨硼替佐米治疗期间伐昔洛韦不同用药方法预防带状疱疹的效果。方法：31例多发性骨髓瘤患者随机分成伐昔洛韦间断应用组和连续应用组，分别观察2组患者带状疱疹发生情况、药物不良反应、抗病毒治疗费用及情绪状态。结果：2组患者治疗期间均未合并带状疱疹，未发生3级以上药物不良反应，间断用药组的抗病毒费用支出低于连续治疗组。患者情绪取决于基础疾病疗效，既往治疗不理想的连续用药组患者有焦虑抑郁表现。结论：伐昔洛韦间断应用能够有效预防硼替佐米治疗期间多发性骨髓瘤患者带状疱疹发生。
배경여목적：수착붕체좌미성공용우다발성골수류적치료，약물도치대상포진격활현상수도관주。본연구탐토붕체좌미치료기간벌석락위불동용약방법예방대상포진적효과。방법：31례다발성골수류환자수궤분성벌석락위간단응용조화련속응용조，분별관찰2조환자대상포진발생정황、약물불량반응、항병독치료비용급정서상태。결과：2조환자치료기간균미합병대상포진，미발생3급이상약물불량반응，간단용약조적항병독비용지출저우련속치료조。환자정서취결우기출질병료효，기왕치료불이상적련속용약조환자유초필억욱표현。결론：벌석락위간단응용능구유효예방붕체좌미치료기간다발성골수류환자대상포진발생。
Background and purpose:Herpes zoster is a common adverse event associated with the use of bortezomib. The objective of this study was to evaluate the efifcacy of different therapeutic regimens of valacyclovir prophylaxis: continuously administration and intermittent administration. Methods: We retrospectively analyzed the efficacy, side effects, expense of valacyclovir and emotional states of 31 patients with multiple myeloma who received bortezomib and valacyclovir prophylaxis. Among them, 14 patients underwent continuously administration of valacyclovir, the other 17 patients underwent intermittent administration. Continuously administration was deifned as daily oral valacyclovir 600 mg without cessation during entire period of bortezomib treatment. Intermittent administration was deifned as patients received valacyclovir at a dose of 600 mg daily during chemotherapy, while discontinue valacyclovir at the intermission time of bortezomib treatment. Results: There were no herpes zoster in patients of 2 arms. Adverse events over grade 3 associated with valacyclovir were not observed. Intermittent administration of valacyclovir showed a superiority of economic beneift. The emotional status were depended on the therapeutic effects of multiple myeloma. For those relapsed or refractory patients, continuously administration of valacyclovir might aggravate depression and anxiety. Conclusion:Intermittent administration of valacyclovir at a dose of 600 mg daily appears to be an effective prophylaxis for herpes zoster in patients receiving bortezomib.